bioMerieux (BMXMF) to Announce Earnings on Tuesday

bioMerieux (OTCMKTS:BMXMF) will likely be announcing its resultson Tuesday, July 28th. Analysts expect bioMerieux to post earnings of $2.44 per share and revenue of $2.2103 billion for the quarter.

bioMerieux Price Performance

Shares of BMXMF stock opened at $80.31 on Tuesday. The stock has a 50 day simple moving average of $81.75 and a two-hundred day simple moving average of $100.94. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. bioMerieux has a fifty-two week low of $77.00 and a fifty-two week high of $152.00.

Analysts Set New Price Targets

BMXMF has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Zacks Research raised bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Piper Sandler started coverage on bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley cut bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Five research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, bioMerieux has an average rating of “Reduce”.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.